Form 8-K · Current report
Zimmer Biomet 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0001136869
- Accession no.
- 0001193125-26-446145
Summary
Zimmer Biomet reported third-quarter 2026 net sales of $2.063 billion, up 3.1% on a reported basis and 3.7% in constant currency, with diluted earnings per share of $1.00 (down 13.8%) and adjusted diluted EPS of $1.90. The company raised its full-year 2026 organic constant-currency revenue growth guidance to 3.0%–3.5% and its adjusted diluted EPS guidance to $8.50–$8.60, citing strength in hips, S.E.T. and Technology & Data, Bone Cement and Surgical franchises, according to Chairman, President and CEO Ivan Tornos.
Key points
- Third-quarter net sales were $2.063 billion, with U.S. sales of $1.2056 billion and international sales of $857.2 million.
- Knees sales fell 3.1% to $767.5 million, while hips rose 6.0% to $536.5 million and S.E.T. rose 6.8% to $578.3 million.
- Operating cash flow was $560.0 million and free cash flow was $372.4 million in the quarter.
- Zimmer Biomet extended a multi-year limited exclusive distribution and supply agreement with THINK Surgical and opened a new Zimmer Biomet Institute facility in Charlotte, N.C.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report. The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.